Cargando…
Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
BACKGROUND: An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-con...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287663/ https://www.ncbi.nlm.nih.gov/pubmed/30584269 http://dx.doi.org/10.2147/OPTH.S177176 |
_version_ | 1783379676617506816 |
---|---|
author | Labetoulle, Marc Schmickler, Stefanie Galarreta, David Böhringer, Daniel Ogundele, Abayomi Guillon, Michel Baudouin, Christophe |
author_facet | Labetoulle, Marc Schmickler, Stefanie Galarreta, David Böhringer, Daniel Ogundele, Abayomi Guillon, Michel Baudouin, Christophe |
author_sort | Labetoulle, Marc |
collection | PubMed |
description | BACKGROUND: An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-containing artificial-tear formulation in patients with DED. METHODS: In a prospective, 6-week, multicenter, double-masked, parallel-group study, patients with DED aged ≥18 years and total ocular surface staining (TOSS) score ≥4 and ≤9 were randomized (1:1) to receive either HPG-HA or SH four times a day for 42 days. Changes from baseline in TOSS (primary end point), impact of dry eye on everyday life (IDEEL) treatment-satisfaction scores (effectiveness and inconvenience), and tear-film breakup time (TFBUT) at day 42 were assessed using a fixed-sequence testing strategy. Noninferiority was assessed on the primary end point based on the upper limit of two-sided 95% CIs for mean treatment difference (HPG-HA or SH) <2 units. RESULTS: In total, 99 patients were randomized (HPG-HA, n= 50; SH, n= 49). At day 42, the least square (LS) mean ± SE change from baseline in TOSS was −1.16±0.24 and −0.92±0.23 in the HPG-HA and SH groups, respectively, and the treatment difference was −0.24±0.33 (95% CI −0.90 to 0.42). Noninfe-riority was demonstrated as the upper limit of the 95% CI was <2 units. LS mean change from baseline at day 42 for HPG-HA vs SH was −3.18 (P=0.4817) in IDEEL treatment-effectiveness scores, −12.56 (P=0.0001) in treatment-inconvenience scores, and 0.30 seconds (P=0.5789) in TFBUT. CONCLUSION: The HPG-HA dual-polymer formulation was noninferior to the SH lubricant eye-drops for improvement in ocular surface staining in DED. HPG-HA did not show improvement over SH in IDEEL treatment-satisfaction scores. No new safety findings were reported. |
format | Online Article Text |
id | pubmed-6287663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62876632018-12-24 Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study Labetoulle, Marc Schmickler, Stefanie Galarreta, David Böhringer, Daniel Ogundele, Abayomi Guillon, Michel Baudouin, Christophe Clin Ophthalmol Original Research BACKGROUND: An artificial-tear formulation containing the dual polymers hydroxypropyl guar (HPG) and hyaluronic acid (HA) is approved for the treatment of dry-eye disease (DED). The present study compared the efficacy and safety of the HPG-HA dual-polymer formulation vs a sodium hyaluronate (SH)-containing artificial-tear formulation in patients with DED. METHODS: In a prospective, 6-week, multicenter, double-masked, parallel-group study, patients with DED aged ≥18 years and total ocular surface staining (TOSS) score ≥4 and ≤9 were randomized (1:1) to receive either HPG-HA or SH four times a day for 42 days. Changes from baseline in TOSS (primary end point), impact of dry eye on everyday life (IDEEL) treatment-satisfaction scores (effectiveness and inconvenience), and tear-film breakup time (TFBUT) at day 42 were assessed using a fixed-sequence testing strategy. Noninferiority was assessed on the primary end point based on the upper limit of two-sided 95% CIs for mean treatment difference (HPG-HA or SH) <2 units. RESULTS: In total, 99 patients were randomized (HPG-HA, n= 50; SH, n= 49). At day 42, the least square (LS) mean ± SE change from baseline in TOSS was −1.16±0.24 and −0.92±0.23 in the HPG-HA and SH groups, respectively, and the treatment difference was −0.24±0.33 (95% CI −0.90 to 0.42). Noninfe-riority was demonstrated as the upper limit of the 95% CI was <2 units. LS mean change from baseline at day 42 for HPG-HA vs SH was −3.18 (P=0.4817) in IDEEL treatment-effectiveness scores, −12.56 (P=0.0001) in treatment-inconvenience scores, and 0.30 seconds (P=0.5789) in TFBUT. CONCLUSION: The HPG-HA dual-polymer formulation was noninferior to the SH lubricant eye-drops for improvement in ocular surface staining in DED. HPG-HA did not show improvement over SH in IDEEL treatment-satisfaction scores. No new safety findings were reported. Dove Medical Press 2018-12-05 /pmc/articles/PMC6287663/ /pubmed/30584269 http://dx.doi.org/10.2147/OPTH.S177176 Text en © 2018 Labetoulle et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Labetoulle, Marc Schmickler, Stefanie Galarreta, David Böhringer, Daniel Ogundele, Abayomi Guillon, Michel Baudouin, Christophe Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study |
title | Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study |
title_full | Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study |
title_fullStr | Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study |
title_full_unstemmed | Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study |
title_short | Efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study |
title_sort | efficacy and safety of dual-polymer hydroxypropyl guar- and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287663/ https://www.ncbi.nlm.nih.gov/pubmed/30584269 http://dx.doi.org/10.2147/OPTH.S177176 |
work_keys_str_mv | AT labetoullemarc efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy AT schmicklerstefanie efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy AT galarretadavid efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy AT bohringerdaniel efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy AT ogundeleabayomi efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy AT guillonmichel efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy AT baudouinchristophe efficacyandsafetyofdualpolymerhydroxypropylguarandhyaluronicacidcontaininglubricanteyedropsforthemanagementofdryeyediseasearandomizeddoublemaskedclinicalstudy |